BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced new preclinical data showing that treatment with PEG-SN38, Enzon’s PEGylated SN38 compound, resulted in significant tumor growth inhibition in mice with tumors resistant to Camptosar® (irinotecan HCl injection). New data also demonstrated excellent in vitro activity of Enzon’s Customized Linker Technology™ when applied to the Locked Nucleic Acid (LNA) antagonists The data were presented at the AACR-NCI-EORTC (American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer) International Conference on “Molecular Targets and Cancer Therapeutics” in San Francisco, California October 22-26, 2007.
